MAPT and Alzheimer disease: Though it may be appropriate to use fly models overexpressing either Aβ or Tau protein to evaluate how compounds affect the AD pathology, a faithful model of AD should feature the overexpression of both Aβ and Tau, as accumulating evidence suggests that Aβ42 plays a central role in the pathogenesis of AD, and Tau acts downstream of Aβ42 as a modulator of the disease progression [10].